Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (19,127,000)	$ (14,400,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	659,000	665,000
Redeemable warrants valuation adjustment	(145,000)	123,000
Abandonment of patents and trademarks		158,000
Gain on sale of fixed assets	(216,000)
Allowance for bad debt recovery		(30,000)
Warrant modification		46,000
Extinguishment of financing obligation and note payable	2,701,000	142,000
Amortization of patent, trademark rights	116,000	68,000
Changes in ROU assets	30,000	(27,000)
Inventory write-off		1,095,000
Impairment of plant property equipment and other assets	1,779,000	135,000
Gain from sale of income tax operating losses	(2,319,000)	(96,000)
Equity-based compensation	1,568,000	1,036,000
Realized gain (loss) on sale of marketable securities	47,000
Amortization of finance and debt issuance costs	47,000	112,000
Change in assets and liabilities:
Accounts receivable	34,000	40,000
Funds receivable from New Jersey operating loss sales	(551,000)	(314,000)
Prepaid expenses and other current assets and other non current assets	1,631,000	671,000
Lease liability	(30,000)	27,000
Accounts payable	(185,000)	(89,000)
Accrued interest expense		231,000
Accrued expenses	(4,000)	39,000
Net cash used in operating activities	(13,965,000)	(10,368,000)
Cash flows from investing activities:
Proceeds from sale of marketable securities	22,292,000	10,044,000
Purchase of marketable securities	(22,535,000)	(18,613,000)
Purchase of property and equipment	(41,000)	(22,000)
Proceeds from sales of property and equipment	245,000
Purchase of patent and trademark rights	(592,000)	(573,000)
Net cash used in investing activities	(631,000)	(9,164,000)
Cash flows from financing activities:
Financing obligation payments	(122,000)	(355,000)
Payoff of note payable	(4,732,000)	(4,330,000)
Proceeds from sale of stock, net of issuance costs	13,042,000	61,248,000
Net cash provided by financing activities	8,188,000	56,563,000
Net (decrease) increase in cash and cash equivalents	(6,408,000)	37,031,000
Cash and cash equivalents at beginning of period	38,501,000	1,470,000
Cash and cash equivalents at end of period	32,093,000	38,501,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Stock issued to settle accounts payable	55,000	15,000
Conversion of Series B preferred	17,000	46,000
Operating Lease - Right of Use Assets	$ 18,000	$ 66,000